Effect of a PCSK9 inhibitor and a statin on cholesterol efflux capacity: A limitation of current cholesterol‐lowering treatments?
Background Cellular cholesterol efflux is a key step in reverse cholesterol transport that may
impact on atherosclerotic cardiovascular risk. The process may be reliant on the availability …
impact on atherosclerotic cardiovascular risk. The process may be reliant on the availability …
Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular …
M Kawashiri, A Nohara, T Higashikata, H Tada… - Atherosclerosis, 2017 - Elsevier
Background and aims Low-density lipoprotein (LDL) apheresis has been used to treat
refractory hyperlipidemia such as familial hypercholesterolemia (FH). Evolocumab, a …
refractory hyperlipidemia such as familial hypercholesterolemia (FH). Evolocumab, a …
Effect of evolocumab on cholesterol synthesis and absorption [S]
M Peach, R Xu, D Fitzpatrick, L Hamilton… - Journal of Lipid …, 2016 - ASBMB
The effects of cholesterol-lowering drugs, including those that reduce cholesterol synthesis
(statins) and those that reduce cholesterol absorption (ezetimibe), on cholesterol absorption …
(statins) and those that reduce cholesterol absorption (ezetimibe), on cholesterol absorption …
Factorial effects of evolocumab and atorvastatin on lipoprotein metabolism
GF Watts, DC Chan, R Dent, R Somaratne… - Circulation, 2017 - Am Heart Assoc
Background: Monoclonal antibodies against proprotein convertase subtilisin kexin type 9
(PCSK9), such as evolocumab, lower plasma low-density lipoprotein (LDL)-cholesterol …
(PCSK9), such as evolocumab, lower plasma low-density lipoprotein (LDL)-cholesterol …
Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans
G Reyes-Soffer, M Pavlyha, C Ngai, T Thomas… - Circulation, 2017 - Am Heart Assoc
Background: Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin
type 9 (PCSK9), lowers plasma low-density lipoprotein (LDL) cholesterol and apolipoprotein …
type 9 (PCSK9), lowers plasma low-density lipoprotein (LDL) cholesterol and apolipoprotein …
PCSK9 modulates the secretion but not the cellular uptake of lipoprotein (a) ex vivo: an effect blunted by alirocumab
EF Villard, A Thedrez, J Blankenstein, M Croyal… - JACC: Basic to …, 2016 - jacc.org
To elucidate how the proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor
alirocumab modulates lipoprotein (a)[Lp (a)] plasma levels, the authors performed a series …
alirocumab modulates lipoprotein (a)[Lp (a)] plasma levels, the authors performed a series …
[HTML][HTML] Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center …
M Palumbo, A Giammanco, F Purrello… - Frontiers in Molecular …, 2022 - frontiersin.org
Proprotein convertase subtilisin/kexin type 9 (PCSK9), beyond regulating plasma LDL
cholesterol (LDL-c), exerts several pleiotropic effects by modulating lipid metabolism in …
cholesterol (LDL-c), exerts several pleiotropic effects by modulating lipid metabolism in …
The effect of Proprotein convertase subtilisin/kexin type 9 inhibition on sterol absorption markers in a cohort of real-world patients
EJ Brandt, LB Benes, L Lee… - Journal of …, 2019 - journals.sagepub.com
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is expressed in multiple
tissues, including the small intestine. The effect of PCSK9 inhibition on cholesterol …
tissues, including the small intestine. The effect of PCSK9 inhibition on cholesterol …
The interrelations between PCSK9 metabolism and cholesterol synthesis and absorption
G Silbernagel, LK Steiner, T Hollstein, G Fauler… - Journal of lipid …, 2019 - ASBMB
Very few studies have investigated the interrelations between proprotein convertase
subtilisin/kexin type 9 (PCSK9) metabolism, cholesterol synthesis, and cholesterol …
subtilisin/kexin type 9 (PCSK9) metabolism, cholesterol synthesis, and cholesterol …
PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein (a) particles in statin-treated patients with elevated lipoprotein (a)
Abstract Background Lipoprotein (a)(Lp (a)) is a low-density lipoprotein (LDL) particle
containing apolipoprotein (a)(apo (a)) covalently linked to apolipoprotein B-100 (apoB) …
containing apolipoprotein (a)(apo (a)) covalently linked to apolipoprotein B-100 (apoB) …